Is Wegovy injection only, or is there now a tablet option?

Picture this: you've just searched 'Wegovy injection' and noticed the word 'tablet' appearing alongside it

That confusion is understandable. For years, weight-management semaglutide in the UK meant a pen you injected once a week. Then in early summer 2026 the options quietly expanded. The MHRA approved Wegovy tablets on 11 June 2026, making them the first oral GLP-1 medicine licensed in the UK for weight loss. A lot of people still assume all GLP-1 medicines are injections, a reasonable assumption until recently, but no longer the full picture.

The injection itself is a pre-filled, once-weekly subcutaneous pen, not a daily injection, which surprises some people who are used to other injectable medicines. You administer it into the skin of your abdomen, thigh, or upper arm, rotating the site each week. The dosing pathway runs from 0.25 mg up through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, titrated roughly every four weeks by your prescriber. A higher 7.2 mg maintenance dose received MHRA approval in January 2026; a dedicated single-dose 7.2 mg pen followed on 14 April 2026. The injection requires refrigeration between 2°C and 8°C, full storage guidance is in the Patient Information Leaflet, and our Wegovy storage requirements page covers the key points.

The tablet works differently at a practical level. It's taken once daily, first thing in the morning on an empty stomach, with a small amount of plain water, no coffee, no food, no other oral medicines for at least 30 minutes afterwards. The dose ladder runs 1.5 mg to 4 mg to 9 mg, reaching a 25 mg maintenance dose. No refrigeration required, which some people find easier when travelling.

What the trial evidence shows, and the one misconception worth clearing up

There's a persistent belief that injections are inherently more powerful than tablets, as if the route of delivery alone determines how much weight you lose. For semaglutide, that isn't quite the right frame. The two forms have been studied in separate trials with different populations, designs, and durations, which makes direct comparison tricky.

The injection at 2.4 mg was studied in the STEP 1 trial (68 weeks), where participants lost around 15% of body weight on average, as published in the New England Journal of Medicine. The oral tablet at 25 mg was studied in the OASIS 4 trial (64 weeks), where participants lost around 13.6% on average regardless of adherence, rising to roughly 17% among those who stayed fully adherent throughout. Neither figure is the whole story: population differences, lifestyle support provided, and individual biology all shape outcomes.

What genuinely matters more than the delivery route is whether the medicine is clinically appropriate for you, whether you can sustain the routine it requires, and whether a prescriber has assessed your full health picture. Our Wegovy injection guide goes into more depth on the pen's clinical profile, including the STEP 1 data.

Who each form is licensed for, and what that means for your options

Both the injection and the tablet are licensed for adults, but their eligibility thresholds are not identical. The injection (at its standard 2.4 mg maintenance dose) is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The same broad framework applies to the tablet, though always subject to the prescriber's full assessment.

The 7.2 mg injection pen approved in April 2026 carries a BMI threshold of 30 or above, it is not currently indicated for BMI below 30 or for the cardiovascular risk-reduction indication. Checking current availability of specific pen formats is something our prescribers confirm at consultation, since availability can shift.

Neither form is recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. Treatment is not licensed for people under 18. These aren't technicalities; they reflect the evidence base, and a prescriber will go through your circumstances before any decision is made. The NHS semaglutide medicines page gives a readable overview of the contraindications across both forms.

For people considering the injection specifically, questions about technique come up often, including where on the body you can inject. The guide to upper-arm injections is worth reading if that's your preferred site.

Getting the right form for you through a clinical assessment

Cost is a factor for many people, and it's worth knowing that private treatment pricing varies by dose, form, and provider. Our Wegovy pricing page gives honest context on what private treatment typically costs in the UK and what a legitimate price should include. What it shouldn't include is a surprise consultation fee or prescription charge on top, at nume, one price covers the consultation, prescription, and free next-working-day delivery.

Choosing between injection and tablet isn't really a lifestyle preference. It's a clinical conversation. Factors like your current medicines, how your digestive system responds to GLP-1 side effects, your daily routine, and your medical history all bear on which form is more likely to work safely and consistently for you. That conversation happens at consultation, reviewed by a real prescriber, not an automated system.

If you'd like to understand your options properly, speak to our prescribers through a free consultation and let them assess whether Wegovy, in whichever form, is the right place to start.